3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
39
Magnetic Resonance Spectroscopy
33
Cyclophosphamide
30
Doxorubicin
24
Biopsy
24
pembrolizumab
22
Temozolomide
22
Radiotherapy
20
Radiation
19
X-Rays
18
Nivolumab
15
Vincristine
13
Irinotecan
13
fludarabine
12
Phantoms, Imaging
12
Ifosfamide
12
Gemcitabine
12
atezolizumab
11
cabozantinib
10
Ipilimumab
9
Bevacizumab
9
liposomal doxorubicin
8
Surgical Procedures, Operative
8
Paclitaxel
8
Immunoglobulin G
8
Etoposide
8
Dactinomycin
7
Carboplatin
7
palbociclib
6
olaparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
SGN-LIV1A
×
Sarcoma
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled